AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34252115 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in individuals under 70 years
Number of subjects: 117405
Study 34252115 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in individuals at intermediate cardiovascular risk
Number of subjects: 117405
Study 34252115 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in individuals at high cardiovascular risk
Number of subjects: 117405
Study 34252115 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) use in individuals at low cardiovascular risk
Number of subjects: 117405
Study 34252115 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine
Number of subjects: 117405
Study 32763240 — intervention group
Group type: EXPERIMENTAL
Intervention: SER-287 after vancomycin preconditioning (daily dosing)
Number of subjects: 58
Study 32763240 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo/placebo group)
Number of subjects: 58
Study 32763240 — intervention group
Group type: COMPARATOR
Intervention: SER-287 (weekly dosing)
Number of subjects: 58
Study 32763240 — intervention group
Group type: COMPARATOR
Intervention: SER-287 (weekly dosing after vancomycin)
Number of subjects: 58
Study 32763240 — intervention group
Group type: EXPERIMENTAL
Intervention: SER-287 (all SER-287 groups)
Number of subjects: 58
Study 32763240 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin/SER-287 groups
Number of subjects: 58
Study 32165550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation content plus additional pain module delivered by a smartphone app
Number of subjects: 14
Study 32165550 — intervention group
Group type: COMPARATOR
Intervention: Muscle relaxation content from the same app (active control)
Number of subjects: 14
Study 32165550 — intervention group
Group type: COMPARATOR
Intervention: Usual care (passive control)
Number of subjects: 14
Study 35398585 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cesarean delivery
Number of subjects: 191
Study 35398585 — intervention group
Group type: COMPARATOR
Intervention: Traditional cesarean delivery
Number of subjects: 191
Study 32795987 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved access to postpartum family planning services including a brochure, up to 6 home visits from trained family planning counselors, free transportation to a family planning clinic, and financial reimbursement for services.
Number of subjects: 2143
Study 32795987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (n=1026)
Number of subjects: 2143
Study 32795987 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=1117)
Number of subjects: 2143
Study 33569973 — intervention group
Group type: COMPARATOR
Intervention: Candidates with no stereotypical attribute (CPX)
Number of subjects: 98
Study 33569973 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidates with purple hair (CPH)
Number of subjects: 98
Study 33569973 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidates with tattoos (CPT)
Number of subjects: 98
Study 33569973 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidates with a Liverpool English accent (CPA)
Number of subjects: 98
Study 32873473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone (usually levofloxacin) monotherapy, 54% of treatments in both settings
Number of subjects: 395
Study 32873473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone monotherapy
Number of subjects: 395
Study 32873473 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobials for more than 7 days
Number of subjects: 395
Study 32873473 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate >25 breaths per minute
Number of subjects: 395
Study 32873473 — intervention group
Group type: EXPERIMENTAL
Intervention: Being on hospice
Number of subjects: 395
Study 32873473 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having dementia
Number of subjects: 395
Study 32873473 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization status
Number of subjects: 395
Study 36208978 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®)
Number of subjects: 0
Study 34058173 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Switch (TS)
Number of subjects: 0
Study 34058173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-Task (DT)
Number of subjects: 0
Study 34058173 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 32174580 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site phacotrabeculectomy
Number of subjects: 40
Study 32174580 — intervention group
Group type: COMPARATOR
Intervention: Twin-site phacotrabeculectomy
Number of subjects: 40
Study 32174580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Single-site and Twin-site)
Number of subjects: 40
Study 34850428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine spray
Number of subjects: 228
Study 34850428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% pH‐balanced chlorine dioxide spray
Number of subjects: 228
Study 34850428 — intervention group
Group type: COMPARATOR
Intervention: Sterile water spray (placebo control)
Number of subjects: 228
Study 32119662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to donate blood
Number of subjects: 515
Study 32119662 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct perceived behavioral control
Number of subjects: 515
Study 32119662 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct subjective norm
Number of subjects: 515
Study 32119662 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct attitude
Number of subjects: 515
Study 32119662 — intervention group
Group type: EXPERIMENTAL
Intervention: Past behavior of blood donation
Number of subjects: 515
Study 33726853 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive thinking training program (16 hours based on materials by Martin Seligman)
Number of subjects: 78
Study 33726853 — intervention group
Group type: COMPARATOR
Intervention: Usual programs (Control group)
Number of subjects: 78
Study 35474448 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-cm interval subcuticular sutures
Number of subjects: 50
Study 35474448 — intervention group
Group type: COMPARATOR
Intervention: 2-cm interval subcuticular sutures
Number of subjects: 50
Study 33277277 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 381
Study 33277277 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 381
Study 34547400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of lipopolysaccharide (LPS) at a dose of 0.6 ng/kg body weight
Number of subjects: 49
Study 34547400 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 49
Study 33524145 — intervention group
Group type: COMPARATOR
Intervention: Nicotinamide Riboside (NR) supplementation at 1000 mg/day for 6 weeks
Number of subjects: 0
Study 33524145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR) at 50 µM or 500 µM in vitro
Number of subjects: 0
Study 33524145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR) supplementation in HFD-fed mice at 400 mg/kg/day for 4 weeks
Number of subjects: 0
Study 32340781 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Frequency Domain Imaging (OFDI) guidance in percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 32340781 — intervention group
Group type: COMPARATOR
Intervention: Intravascular Ultrasound (IVUS) guidance in percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 616493060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) supplementation (140ml of NO3‐rich beetroot juice containing 8.0mmol [NO3‐]) for seven days
Number of subjects: 9
Study 35466449 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Citrate (Ca-Cit)
Number of subjects: 24
Study 35466449 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate (CaCO3)
Number of subjects: 24
Study 33760791 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver machine perfusion (MP)
Number of subjects: 0
Study 36307361 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTA)
Number of subjects: 75
Study 36307361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 33893066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-T fast MRI (n = 213)
Number of subjects: 311
Study 33893066 — intervention group
Group type: COMPARATOR
Intervention: mpMRI (n = 98)
Number of subjects: 311
Study 33424487 — intervention group
Group type: EXPERIMENTAL
Intervention: Health communication channels for hepatitis B virus management
Number of subjects: 600
Study 34467477 — intervention group
Group type: EXPERIMENTAL
Intervention: Different boron concentrations in the substrate
Number of subjects: 0
Study 33517160 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI reading by skilled musculoskeletal radiologists
Number of subjects: 20
Study 35078552 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C)
Number of subjects: 9
Study 33095715 — intervention group
Group type: EXPERIMENTAL
Intervention: PK-clustering approach with visual analytics user interface
Number of subjects: 0
Study 33095715 — intervention group
Group type: COMPARATOR
Intervention: Traditional clustering algorithms (implied control)
Number of subjects: 0
Study 35512731 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week break from social media
Number of subjects: 154
Study 35512731 — intervention group
Group type: COMPARATOR
Intervention: Continue to use social media as usual
Number of subjects: 154
Study 33370165 — intervention group
Group type: COMPARATOR
Intervention: Salacia chinensis extract (150, 300, or 600 mg)
Number of subjects: 0
Study 33370165 — intervention group
Group type: COMPARATOR
Intervention: Salacia chinensis extract (600 mg/day)
Number of subjects: 0
Study 36484021 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxoprofen Sodium Cataplasm combined with extracorporeal shock wave therapy (ESWT) and transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 100
Study 36484021 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxoprofen Sodium Cataplasm alone
Number of subjects: 100
Study 36484021 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy alone
Number of subjects: 100
Study 36484021 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen Cataplasm combined with physiotherapy
Number of subjects: 100
Study 36126105 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 1 (diffusion optics lenses)
Number of subjects: 256
Study 36126105 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 2 (diffusion optics lenses)
Number of subjects: 256
Study 36126105 — intervention group
Group type: COMPARATOR
Intervention: Control lenses
Number of subjects: 256
Study 33867500 — intervention group
Group type: EXPERIMENTAL
Intervention: Land walking
Number of subjects: 63
Study 33867500 — intervention group
Group type: EXPERIMENTAL
Intervention: Water walking
Number of subjects: 63
Study 33867500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 33867500 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise groups
Number of subjects: 63
Study 35215461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and exercise intervention (bi‐weekly counselling for individualized energy and high dairy protein diet; walking goal of 10,000 steps/day)
Number of subjects: 241
Study 35215461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and exercise intervention
Number of subjects: 241
Study 35215461 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 241
Study 33231839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorion membrane (CM)
Number of subjects: 15
Study 33231839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorion membrane (CM) + platelet rich fibrin (PRF)
Number of subjects: 15
Study 33231839 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 32758298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous melatonin (IVM) 5 mg/kg/day for 7 days
Number of subjects: 18
Study 32758298 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5 mg/kg/day for 7 days
Number of subjects: 18
Study 35278402 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 0
Study 35278402 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 35278402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33267815 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical Dialysis (TD)
Number of subjects: 10
Study 33267815 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical Dialysis + Exercise (TD + E)
Number of subjects: 10
Study 33267815 — intervention group
Group type: COMPARATOR
Intervention: Cold Dialysis (CD)
Number of subjects: 10
Study 33267815 — intervention group
Group type: COMPARATOR
Intervention: Cold Dialysis + Exercise (CD + E)
Number of subjects: 10
Study 34554015 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal allocation to treatments in a sequential multiple assignment randomized trial
Number of subjects: 0
Study 34554015 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximin optimal design methodology
Number of subjects: 0
Study 32077706 — intervention group
Group type: EXPERIMENTAL
Intervention: Label as 'client'
Number of subjects: 526
Study 32077706 — intervention group
Group type: COMPARATOR
Intervention: Label as 'patient'
Number of subjects: 526
Study 32077706 — intervention group
Group type: COMPARATOR
Intervention: Label as 'consumer'
Number of subjects: 526
Study 32077706 — intervention group
Group type: COMPARATOR
Intervention: Label as 'service user'
Number of subjects: 526
Study 34091468 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 34
Study 34091468 — intervention group
Group type: COMPARATOR
Intervention: Steroid Injection
Number of subjects: 34
Study 34091468 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Form Health Survey
Number of subjects: 34
Study 34091468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dallas Pain Questionnaire
Number of subjects: 34
Study 34940059 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive doses of levothyroxine
Number of subjects: 98
Study 34940059 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH concentration <0.1 µU/mL
Number of subjects: 98
Study 34940059 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH concentration 0.4‐4.0 µU/mL
Number of subjects: 98
Study 34940059 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH concentration 0.1‐0.39 µU/mL
Number of subjects: 98
Study 34940059 — intervention group
Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 98
Study 32728920 — intervention group
Group type: EXPERIMENTAL
Intervention: NAMI Provider Education Program - a 15-h contact-based adjunctive curriculum
Number of subjects: 231
Study 32728920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 231
Study 34036235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (Bev plus CTx)
Number of subjects: 132
Study 34036235 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (CTx) alone
Number of subjects: 132
Study 32272024 — intervention group
Group type: EXPERIMENTAL
Intervention: sweetened-milk (FED)
Number of subjects: 14
Study 32272024 — intervention group
Group type: COMPARATOR
Intervention: water control (FAST)
Number of subjects: 14
Study 35077429 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforating fat injections (2.6 ± 1.6 ml of fat injected per foot at one to two sites)
Number of subjects: 14
Study 35077429 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforating fat injections
Number of subjects: 14
Study 35077429 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed for 6 months, injected, and then followed for 6 months)
Number of subjects: 14
Study 35077429 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 34149004 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU/leucovorin
Number of subjects: 281
Study 34149004 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin/cisplatin/5‐FU
Number of subjects: 281
Study 34149004 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU chemoradiation
Number of subjects: 281
Study 32295531 — intervention group
Group type: EXPERIMENTAL
Intervention: BCM group (bioimpedance guided dry weight assessment)
Number of subjects: 445
Study 32295531 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 445
Study 32295531 — intervention group
Group type: EXPERIMENTAL
Intervention: BCM group
Number of subjects: 445
Study 35172875 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 310
Study 35172875 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 310
Study 33378139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretomanid 400 mg
Number of subjects: 74
Study 33378139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretomanid 1000 mg
Number of subjects: 74
Study 33378139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretomanid 400 mg plus Moxifloxacin 400 mg
Number of subjects: 74
Study 33378139 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 74
Study 33378139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 33025342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod (0.23 mg on days 1-4, 0.46 mg on days 5-7, 0.92 mg on days 8-10, and 1.84 mg on days 11-30) + Pseudoephedrine (PSE) 60 mg on day 30
Number of subjects: 56
Study 33025342 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Pseudoephedrine (PSE) 60 mg on day 30
Number of subjects: 56
Study 33839753 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical and oral antibiotic bowel preparation (MOABP)
Number of subjects: 381
Study 33839753 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation (NBP)
Number of subjects: 381
Study 33327255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study 35476749 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle intervention (3-month program, 3 one-hour sessions per week)
Number of subjects: 96
Study 35543479 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program based on 5 A's model
Number of subjects: 96
Study 35543479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 96
Study 35304275 — intervention group
Group type: COMPARATOR
Intervention: Low dose Cassia seed powder (0.3 g once daily)
Number of subjects: 94
Study 35304275 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Cassia seed powder (3.0 g once daily)
Number of subjects: 94
Study 32732745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone injection
Number of subjects: 40
Study 32732745 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 40
Study 35367469 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 20 μg/m3
Number of subjects: 13
Study 35367469 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 50 μg/m3
Number of subjects: 13
Study 35367469 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 150 μg/m3
Number of subjects: 13
Study 35367469 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 13
Study 33894833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 1064
Study 33894833 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 1064
Study 34304516 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG combined with methylene blue (Group A)
Number of subjects: 90
Study 34304516 — intervention group
Group type: COMPARATOR
Intervention: Only methylene blue (Group B)
Number of subjects: 90
Study 33861813 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based social-emotional programme (emoTIC)
Number of subjects: 119
Study 35217941 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-µm cap thickness
Number of subjects: 94
Study 35217941 — intervention group
Group type: EXPERIMENTAL
Intervention: 140-µm cap thickness
Number of subjects: 94
Study 35217941 — intervention group
Group type: COMPARATOR
Intervention: Both 120-µm and 140-µm cap thicknesses
Number of subjects: 94
Study 32847731 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Ultrabiotic 60™ and Saccharomyces boulardii during international competition)
Number of subjects: 19
Study 32847731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 35799654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestration decompression
Number of subjects: 135
Study 35799654 — intervention group
Group type: COMPARATOR
Intervention: Curettage of cysts
Number of subjects: 135
Study 33432422 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐Security Vitrification™ - HSV
Number of subjects: 737
Study 33432422 — intervention group
Group type: COMPARATOR
Intervention: Cryotop® open system
Number of subjects: 737
Study 33935064 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace counseling program with a physical therapist or nurse once a week for 12 weeks
Number of subjects: 37
Study 33935064 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace counseling program
Number of subjects: 37
Study 33935064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 37
Study 33819528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention targeting loss of control over eating (inhibitory control training and implementation intentions)
Number of subjects: 78
Study 33819528 — intervention group
Group type: COMPARATOR
Intervention: Food-specific or general intervention
Number of subjects: 78
Study 32540090 — intervention group
Group type: EXPERIMENTAL
Intervention: Classwide math intervention
Number of subjects: 537
Study 36087008 — intervention group
Group type: EXPERIMENTAL
Intervention: Batoclimab 680 mg with IVMP
Number of subjects: 9
Study 36087008 — intervention group
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg with IVMP
Number of subjects: 9